Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|November 15, 2011
TAKE Solutions Partners with MENE Research to Capture Emerging Pharma Markets Globally
Advertisement
TAKE Solutions Ltd.
has strengthened its Drug Safety and Pharmacovigilance solutions and services offering to cater to the growing needs of Pharma Emerging nations. The company has partnered with
MENE Research
wherein they together will cater to the Drug Safety requirements of Middle East, Europe, and West Asian countries.
Both the companies together will work towards providing the life science industry with strategy, solutions and services for drug safety operations thus ensuring global regulatory compliance and effective patient safety methodologies is followed. This partnership becomes strong by the fact that TAKE already has to its credit creating a framewokr—SafetyReady—along with a thought leadership in Drug Safety and Pharmacovigilance segments and Mene Research’s regional experience in Middle East, Europe, West Asia, etc.
TAKE Solutions extended Drug Safety and Pharmacovigilance Service Offerings with recent launch of SafetyReady for Oracle Argus Safety Suite Customers. Read
more
.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
Where AI Governance in Clinical Development Falls Short
5